suPAR-Guided AKI Prevention With Targeted Antagonist Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective biomarkers for predicting and preventing acute kidney injury (AKI), particularly in patients at high risk due to medical procedures or conditions like contrast-induced nephropathy, and there are limited therapeutic options to mitigate this condition.
Innovation Solution
Measuring soluble urokinase plasminogen activator receptor (suPAR) levels in biological samples and administering a therapeutically effective amount of an agent that antagonizes suPAR, such as antibodies or antigen-binding fragments, to inhibit suPAR signaling in subjects at risk for AKI.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If suPAR levels are measured and antagonistic agents are administered to subjects at risk, then the risk and severity of AKI are reduced, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent measures suPAR levels before medical procedures to identify at-risk patients in advance. By detecting elevated suPAR levels prior to contrast agent administration or other nephrotoxic exposures, the system enables preemptive intervention with antagonistic agents, preventing AKI before it occurs rather than treating it after onset.
Solution Approach 2:
The patent introduces suPAR antagonistic agents (such as monoclonal antibodies or soluble receptors) as intermediary substances that block the harmful interaction between suPAR and its receptor. These agents serve as mediators that prevent suPAR from binding to podocyte receptors, thereby interrupting the pathogenic pathway without requiring direct modification of the underlying disease process.
2Reliability
If suPAR antagonistic agents are administered to all at-risk patients, then AKI prevention is improved, but the cost of treatment increases
Solution Approach 1:
The patent applies treatment selectively rather than universally by identifying patients with elevated suPAR levels as the specific subgroup that benefits from antagonistic therapy. This targeted approach ensures that expensive pharmacological interventions are reserved for high-risk individuals rather than being administered to all patients, thereby optimizing resource allocation and reducing overall treatment costs.
Solution Approach 2:
The patent uses suPAR level measurement as a threshold parameter to stratify patients into risk categories. By establishing cutoff values for suPAR concentrations, the system transforms a continuous biomarker into discrete risk stratification groups, enabling cost-effective decision-making about which patients warrant expensive preventive therapy versus those who can be managed with standard care.
3Loss of time
If suPAR levels are used to identify at-risk subjects, then early recognition of AKI risk is improved, but the availability of clinically ready biomarkers is limited
Solution Approach 1:
The patent establishes suPAR measurement protocols to be performed before medical procedures, creating a standardized preliminary screening process. By integrating suPAR testing into pre-procedural workups, the system ensures timely risk identification without requiring complex post-procedure monitoring or delayed intervention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively reduces the risk and severity of AKI by inhibiting suPAR activity, thereby protecting kidney function and improving patient outcomes.
Implementation Method 1
administering a therapeutically effective amount of an agent that antagonizes soluble urokinase plasminogen activator receptor (suPAR), such as antibodies or antigen-binding fragments, to inhibit suPAR signaling
Data Source
AI summary
Methods and compositions for treating acute kidney injury in a subject are provided. The methods include measuring or having measured a level of soluble urokinase plasminogen activator receptor (suPAR) in a biological sample from the subject, determining or having determined the level of suPAR in the sample compared to a control suPAR level, and administering a therapeutically effective amount of an agent that antagonizes soluble urokinase plasminogen activator receptor (suPAR) to the subject having an elevated level of suPAR relative to the control suPAR level.